Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 289

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 289
---
 progress associated with the Company’s gene therapy technologies, including the limited approval by the FDA of ELEVIDYS during 2023 and expanded approval in 2024, by inspecting internal meeting minutes and interviewing research and development personnel of the Company and assessed the potential impact of those technologies on expected future demand for certain raw materials inventory. We inquired of manufacturing personnel and evaluated the expiry of certain raw materials. We also read publicly available information to identify other competitor entities with RNA-targeted therapeutic or gene therapy products that could impact the Company’s estimates of expected future demand. 

/s/ KPMG LLP

We have served as the Company’s auditor since 2002. 

Boston, Massachusetts

February 28, 2025

F-3

Sarepta Therapeutics, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

    As of December 31,

    2024

    2023

    Assets

    Current assets:

    Cash and cash equivalents
     
    $
    1,103,010

    $
    428,430

    Short-term investments

    251,782

    1,247,820

    Accounts receivable, net

    601,988

    400,327

    Inventory

    749,960

    322,859

    Manufacturing-related deposits and prepaids

    276,262

    102,181

    Other current assets

    90,461

    77,714

    Total current assets

    3,073,463

    2,579,331

    Property and equipment, net

    340,336

    227,154

    Right of use assets

    148,310

    129,952

    Non-current inventory

    187,986

    191,368

    Non-current investments

    133,163

    —

    Other non-current assets

    79,915

    136,771

    Total assets
     
    $
    3,963,173

    $
    3,264,576

    Liabilities and Stockholders’ Equity

    Current liabilities:

    Accounts payable
     
    $
    214,442

    $
    164,918

    Accrued expenses

    373,513

    314,997

    Deferred revenue, current portion

    130